Premium
Interferon response to dipyridamole in lupus erythematosus patients
Author(s) -
KONSTANTINOV K.,
GALABOV A.,
MASTIKOVA M.
Publication year - 1989
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/j.1365-2133.1989.tb01400.x
Subject(s) - dipyridamole , medicine , lupus erythematosus , immunology , stimulation , systemic lupus erythematosus , interferon , in vivo , autoimmune disease , disease , antibody , biology , microbiology and biotechnology
SUMMARY Studies in patients with autoimmune disorders strongly support a role for interferon (IFN) in the disease process. In the present study we investigated the in vivo production of α‐IFN in lupus erythematosus patients after stimulation with dipyridamole, recently characterized as an α‐IFN inducer in mice and humans. Levels of IFN were measured in serum samples from 22 patients with systemic lupus erythematosus (SLE) and 12 patients with discoid lupus erythematosus (DLE) before and 24 h after dipyridamole administration. IFN activity was assayed on human and bovine cells in parallel. Initial serum concentrations of α‐IFN in SLE patients were markedly elevated. The percentage of DLE positive responders to dipyridamole induction was about twice as high as that found for SLE. Studies of factors responsible for IFN production in lupus erythematosus might result in better understanding of the relationship between DLE and SLE.